POS-327 THE COST OF END OF LIFE INPATIENT ENCOUNTERS IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE UNITED STATES

• M. ARNOLD,
• J.J. Garcia Sanchez,
• J.J. Carrero,
• G. James,
• H. Heerspink,
• A. Abdul Sultan,
• C. Lam,
• T. Chen,
• S. Nolan,
• C. Pollock,
• R. Pecoits-Filho

Affiliations

M. ARNOLD

AstraZeneca, None, Cambridge, United Kingdom

J.J. Garcia Sanchez

AstraZeneca, None, Cambridge, United Kingdom

J.J. Carrero

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden

G. James

AstraZeneca, None, Cambridge, United Kingdom

H. Heerspink

University of Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands

A. Abdul Sultan

AstraZeneca, None, Cambridge, United Kingdom

C. Lam

National Heart Centre, Department of Cardiology, Singapore, Singapore; Duke-NUS Medical School, None, Singapore, Singapore

T. Chen

AstraZeneca, None, Gaithersburg, United States

S. Nolan

AstraZeneca, None, Cambridge, United Kingdom

C. Pollock

Kolling Institute- Royal North Shore Hospital- University of Sydney, None, Sydney, Australia

R. Pecoits-Filho

School of Medicine- Pontifical Catholic University of Parana, None, Curitiba, Brazil; Arbor Research Collaborative for Health, None, Ann Arbor, United States